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ABSTRACT
Particle beam therapy (PBT), including proton and carbon ion therapy, is an emerging innovative treatment for
cancer patients. Due to the high cost of and limited access to treatment, meticulous selection of patients who
would beneﬁt most from PBT, when compared with standard X-ray therapy (XRT), is necessary. Due to the
cost and labor involved in randomized controlled trials, the model-based approach (MBA) is used as an alterna-
tive means of establishing scientiﬁc evidence in medicine, and it can be improved continuously. Good databases
and reasonable models are crucial for the reliability of this approach. The tumor control probability and normal
tissue complication probability models are good illustrations of the advantages of PBT, but pre-existing NTCP
models have been derived from historical patient treatments from the XRT era. This highlights the necessity of
prospectively analyzing speciﬁc treatment-related toxicities in order to develop PBT-compatible models. An
international consensus has been reached at the Global Institution for Collaborative Research and Education
(GI-CoRE) joint symposium, concluding that a systematically developed model is required for model accuracy
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and performance. Six important steps that need to be observed in these considerations include patient selection,
treatment planning, beam delivery, dose veriﬁcation, response assessment, and data analysis. Advanced technolo-
gies in radiotherapy and computer science can be integrated to improve the efﬁcacy of a treatment. Model valid-
ation and appropriately deﬁned thresholds in a cost-effectiveness centered manner, together with quality
assurance in the treatment planning, have to be achieved prior to clinical implementation.
Keywords: particle beam therapy; normal tissue complication probability; model-based approach; GI-CoRE
INTRODUCTION
Thanks to support from the Japanese Government and Hokkaido
University, a joint symposium has emerged for collaboration between
the Global Institution for Collaborative Research and Education, the
Global station for quantum medical science and engineering (GI-CoRE
GSQ), the Global Station for Big data and Cybersecurity (GSB), and
the Institute for Genetic Medicine (IGM), Hokkaido University. The
scope of the symposium focused on a model-based approach (MBA)
to tumor control probability (TCP) and normal tissue complication
probability (NTCP) for particle beam therapy (PBT) as a step toward
an international consensus. Highly respected speakers from 10 institu-
tions (the University Medical Center Groningen; the Stanford Cancer
Institute and Stanford University Medical Center; the Mayo Clinic; the
University of Texas MD Anderson Cancer Center, the Johns Hopkins
University School of Medicine; the University of Technology Sidney;
the National Institute of Radiological Science in Chiba; Osaka University;
Kobe Pharmaceutical University; and Hokkaido University) were
invited to present their scientiﬁc knowledge related to the establish-
ment of a global consensus on how to assess treatment efﬁcacy and
toxicity with PBT. The principles of MBA, big data analysis, funda-
mental radiation biology, radiation treatment planning systems, can-
cer care coordination, and medical economics on particle beam therapy
were comprehensively discussed.
The goal of this symposium was to collaboratively develop an
internationally accepted model for identifying patients and tumors
that will derive the most beneﬁt from PBT, in consideration of the
high cost of developing and implementing this therapy.
MODEL-BASED APPROACH
A number of retrospective studies have demonstrated the dosimetric
and clinical beneﬁts of PBT for several tumor sites, but a randomized
controlled trial (RCT) of PBT versus standard X-ray therapy (XRT) is
still expected to be needed in order to obtain Level I evidence in med-
ical practice. However, there are a number of obstacles to conducting
an RCT in terms of ethical and pragmatic issues [1, 2]. An MBA is an
alternative option for aiding in clinical decision-making for the
Radiation Oncology Society, where evolving technologies are rapidly
being developed. Without randomization, patient selection biases can
be eliminated by stratiﬁcation based on speciﬁed characteristics when
applying the model; for example, the NTCP model for radiation-
induced liver disease will be different from that for patients with Child–
Pugh A versus Child–Pugh B–C. In the multivariable model, the clinical
and non-clinical (including dosimetric) features of individual patients
will be included and analyzed to produce the model predicting speciﬁc
treatment-related toxicities. Using an appropriate statistical method, the
effect of each variable is weighted by a coefﬁcient value and integrated
with other variables for the same patient, leading to a personalized
predictive score. In order to achieve appropriate patient selection for
PBT, a model with tailor-made criteria is eagerly anticipated to help
decide the details of the RCT. Minimal requirements for rigorous mod-
els include prospective data collection, sufﬁcient numbers of patients
and events, multivariable analysis, available clinical decision rules,
internal validation, and model performance testing [3]. The concept of
MBA patient selection for PBT was ﬁrst introduced by the University
of Groningen, the Netherlands [4, 5] and successfully approved by the
Dutch Health Council and the Dutch Health Care Insurance Board.
Practically, patients will be eligible for proton therapy if individually
applied validated NTCP models predict low levels of toxicity.
There are several types of TCP and NTCP models. The historical
Webb TCP model [6] and Lyman–Kutcher–Burman NTCP model [7, 8]
are useful for a comparison between radiation modalities, but differ-
ences in biological and absorbed doses are still a concern, especially
when charged particle or non-conventional fractionation is used [9, 10].
Recently, researchers from Hokkaido University have systematically
reviewed NTCP models for liver tumors in the literature and found
heterogeneous results among the models, although the same patient
data were applied (unpublished results); thus, an international con-
sensus on NTCP models is needed. Explanations for the variation of
results generated by the different models may lie in the diversity of
patients, diseases, and treatment regimens. The limitation of the
approach is a result of the XRT-derived NTCP models being assumed
to be valid for proton-based treatments. Despite validity assertions for
head and neck cancers[11], it is recommended that speciﬁc treatment-
related toxicities should be prospectively analyzed and the models
reﬁned in order to validate PBT-compatible NTCP models.
PROPOSED SYSTEMATIC DEVELOPMENT OF
TCP/NTCP MODELS
The consensus that has been drawn from this international symposium
is that a systematically developed model is required. Six important steps
should be scrutinized to ensure model accuracy and performance, as
illustrated in Fig. 1.
Patient selection
The rationale for patient selection is of paramount importance, and is a
good starting point for a mutually agreed study design. Inclusion and
exclusion criteria, as well as study endpoints, must be clear and clinically
meaningful, and they will signiﬁcantly impact the clinical outcomes.
Treatment planning
Advanced technologies have emerged for improving the efﬁcacy of radi-
ation treatments. First, for target delineation, computed tomography
(CT), magnetic-resonance imaging (MRI), and positron-emitting tom-
ography (PET)/CT all provide good image quality with high spatial
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resolution. Four-dimensional CT (4DCT) accounting for respiratory-
dependent organ motion further improves the temporal resolution for
moving tumors. In addition, molecular imaging–based radiation treat-
ment planning and monitoring are currently evolving: for example, hyp-
oxia imaging using 18Fluorine-labeled ﬂuoromisonidazole (18F-FMISO)
[12] and Caspase-3-sensitive nanoaggregation MRI (C-SNAM) [13].
Second, sophisticated treatments such as intensity-modulated proton
therapy need to be subject to robust optimization and evaluation, since
small errors could jeopardize the TCP or worsen the NTCP, so estab-
lishing the therapeutic window while considering the predicted TCP/
NTCP is critically helpful in the treatment planning step. Third, a
biological-based treatment planning using Monte Carlo simulation
increases plan accuracy by comprehensively considering PBT uncertain-
ties together with biological doses from relatively high linear energy
transfer (LET), as well as from the physics of particle interactions and
tissue inhomogeneity and its scattering effects [14, 15]. Finally, appro-
priate fractionation schemes must be carefully selected by optimization
of both physical and biological proﬁles [16]. These innovations will
provide treatment plans with reliably supported decision-making.
Beam delivery
Due to the effect of dose uncertainties on the accuracy of model-based
patient selection [17], the treatment plan robustness and differences
between planned and delivered dose distributions need to be investi-
gated. The accuracy of the beam delivery requires reliable beam proﬁles
and minimal uncertainties in beam range and set-up errors. Precise
tumor positioning can be achieved, mainly by appropriate patient
immobilization, on-board imaging (OBI), and effective motion mitiga-
tion of interplay effects. Orthogonal X-ray and cone-beam computed
tomography (CBCT) are the commonly used OBI methods. They
facilitate beam delivery and tumor margin restrictions, as well as correc-
tion for interfraction motion and volumetric changes during the treat-
ment, leading to a signiﬁcant decrease in NTCP without compromising
TCP [18–20]. Several motion management strategies have been pro-
posed. Real-time tumor-tracking radiotherapy (RTRT) is the most
promising technology and can be integrated with a proton spot-scanning
system, a so called real-time tumor-tracking scanning proton ther-
apy system [21].
Dose veriﬁcation
Actual dose distribution veriﬁcation involves monitoring of beam
proﬁles, tumor position and organ motion. Acquirement of the
delivered dose accumulation in the patient is necessary when incor-
porated with clinical outcomes in order to generate accurate TCP/
NTCP models. Related to this issue, it is a challenge to acquire the
3D delivered dose distribution during the treatment scans rapidly
enough to be able to make real-time treatment decisions.
Response assessment
During and after treatment, regular follow-up of treatment out-
comes and toxicity is needed. Data collection and organization are
critical parts of the research in order to maintain the study integrity.
Given that the validity of the study improves with the number of
study subjects, multi-institutional data aggregation will be useful. For
instance, the Mayo clinic has an outcomes warehouse for data-sharing
among their three regional sites. The warehouse data consists of (i) hos-
pital registration (demographic data and death status); (ii) Electronic
Medical Record or EMR (diagnosis, treatment and physician-reported
toxicity); (iii) patient-reported outcomes (PROs) survey (patient-
reported toxicity and quality of life); and (iv) dose–volume histogram
(DVH) data. Such a database, including treatment outcomes and tox-
icity, can be comprehensively analyzed in order to develop reliable
TCP/NTCP models.
Data analysis
Good collaboration among clinicians, statisticians and informaticists
is necessary for clinical and dosimetric data analysis. The evolving
machine-learning methods are performed to convert the knowledge
into clinical prediction using data science models. For example, the
Johns Hopkins ‘Oncospace’ software collects clinical information
and DVH data of prior patients [22].The results of speciﬁc clinical
aspects can be drawn from the analysis of a large database and
Patient
selection
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Fig. 1. Six critical steps in developing an accurate, highly effective and useful model in radiotherapy.
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incorporated into the treatment plans of new patients to improve
safety and quality of life. This is termed a knowledge-based planning
approach. In the future, genomics and radiomics can be integrated
and used to further develop the model.
After model development, the next mandatory step is model val-
idation in order to determine the performance, accuracy and gener-
alization of the model. The quality of TCP/NTCP models is assessed
by internal and external validation of the model in different groups of
patients using data from the same and different institutions, respect-
ively. In addition, thanks to advances in computer science, large data-
base analyses using a model-based machine-learning approach can be
used to intermittently validate the model by integration of current
patient data in the validation step. This will maintain the good quality
of the models. Eventually, the fully developed complete model would
be able to conﬁdently determine tumors and patients who will poten-
tially beneﬁt from PBT.
OPINIONS IDENTIFYING THE
SHORTCOMINGS OF A MODEL-BASED
APPROACH
The limitations of a model-based patient selection for PBT include the
deductions made from XRT-derived models, unknown thresholds of
risk/beneﬁt for determining the use of PBT, and the quality of treat-
ment planning. Even with the existing models derived from XRT data,
the model validation for PBT treatment has to be conﬁrmed, for
example, in the Blanchard study on head and neck cancers [11].
However, some statistical issues remain unresolved: for example, stud-
ies on NTCP models did not consider model uncertainties. This could
lead to random errors and misinterpretations of the results [17].
Additionally, appropriate thresholds must be deﬁned at speciﬁc end-
points for each particular tumor on a cost–effectiveness basis. Due to
the diversity of opinion about the cost effectiveness of PBT, it is difﬁ-
cult to generate a general rule of reimbursement among institutions
and countries. The cost depends on the treatment cost and the cost of
care after treatment, which is negotiable at the level of the institution.
The incremental cost–effectiveness ratio (ICER), considering increase
in treatment costs versus improvements in quality-adjusted life years
(QALYs), can be performed in a model-based cost–effectiveness ana-
lysis [23]. If the ICER of PBT exceeds the willingness-to-pay threshold,
a PBT is not a cost-effective treatment compared with standard XRT.
With this method, appropriate ΔNTCP thresholds can be identiﬁed.
Further, the treatment planning for IMRT can intentionally be made
suboptimal in order to make a PBT look better in calculating the
ΔNTCP, even when the TCP is the same. This shows the need for
quality assurance in treatment planning.
CONSENSUS FROM THE GI-CORE JOINT
SYMPOSIUM
The MBA is helpful from the view point of the costs and work load
involved in an RCT, although the RCT is still the gold standard at pre-
sent. The MBA can be seen as an alternative measure of evidence-based
medicine that needs to be improved continuously. Good databases and
reasonable TCP and NTCP models are crucial for the reliability of this
approach. The optimal solution may lie in between the RCT and MBA;
speciﬁcally, using the RCT as the gold standard and the MBA as a use-
ful measure for selecting patients for the RCT. This could allow the
number of patients who are required for an RCT to be smaller if an
MBA is used. Practically, the government and other stakeholders in
health insurance must agree to an MBA, despite the consensus among
clinicians. Hopefully, Japanese Proton Beam Therapy Institutions will
be interested in analyzing their large data volumes for an establishment
of the MBA.
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